Key result
A height loss of ≥0.6 cm/year was independently associated with an increased risk of major adverse cardiac and cerebral events compared to a height loss of <0.3 cm/year (adjusted HR 1.25).
Why the study?
Despite evidence for an inverse relationship between adult height and cardiovascular disease incidence, the clinical significance of height loss in cardiovascular disease remains to be elucidated.
Does height loss increase the risk of major adverse cardiac and cerebral events in a Korean population?
Cohort (n=127,573)
Does height loss increase the risk of major adverse cardiac and cerebral events in a Korean population?
Greater annual height loss is independently associated with an increased risk of major adverse cardiac and cerebral events.
Answers are grounded in this paper and cite their sources.
Greater height loss was associated with higher CVD incidence; hypothesis-generating and should not yet change practice.
Background Height declines with age, and its degree differs among individuals. Despite epidemiologic evidence for the inverse relationship between adult height and cardiovascular disease (CVD) incidence, the clinical significance of height loss in CVD remains to be elucidated. Therefore, this study investigated the association between height loss and CVD incidence. Methods In total, 127,573 Korean participants were enrolled; their heights were monitored from 2002 to 2011. The annual height loss (cm/year) was the difference between the first and last height measurements within the observation period divided by the number of years. The participants were classified as Group 1 (height loss: <0.3 cm/year; n = 102,554), Group 2 (height loss: 0.3– < 0.6 cm/year; n = 17,324), or Group 3 (height loss: ≥0.6 cm/year; n = 7,695). Results The cumulative major adverse cardiac and cerebral event (MACCE: cardiac death, non-fatal myocardial infarction, and unplanned hospitalization for heart failure or stroke) incidence rate was 3.6% for Group 1, 4.5% for Group 2, and 5.2% for Group 3. Group 2 (hazard ratio [HR] = 1.27, 95% confidence interval [CI] = 1.17–1.37) and Group 3 (HR = 1.46, 95% CI = 1.32–1.62) had a significantly higher incidence of MACCE than Group 1. In the model adjusted for age, sex, comorbidities, income level, body mass index, smoking, and drinking status, the MACCE risk was higher in Group 2 (HR = 1.11, 95% CI = 1.07–1.20) and Group 3 (HR = 1.25, 95% CI = 1.13–1.39) than in Group 1. Conclusion The degree of height loss was independently associated with CVD occurrences in the Korean population.
No takes yet. Share an insight, caveat, or question.
Moon et al. (2022) conducted a cohort in Cardiovascular disease (n=127,573). Height loss ≥0.6 cm/year vs. Height loss <0.3 cm/year was evaluated on Major adverse cardiac and cerebral events (MACCE) (HR 1.25, 95% CI 1.13-1.39, p=<0.0001). A height loss of ≥0.6 cm/year was independently associated with an increased risk of major adverse cardiac and cerebral events compared to a height loss of <0.3 cm/year (adjusted HR 1.25).
Synapse has enriched 10 related papers. Consider them for comparative context: